Stock Analysis
InDex Pharmaceuticals Holding Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag
InDex Pharmaceuticals Holding (STO:INDEX) Full Year 2023 Results
Key Financial Results
- Revenue: kr97.5m (up by kr96.4m from FY 2022).
- Net loss: kr95.3m (loss narrowed by 5.1% from FY 2022).
- kr0.18 loss per share (improved from kr0.19 loss in FY 2022).
INDEX Products In Clinical Trials
- Phase III: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
InDex Pharmaceuticals Holding EPS Beats Expectations, Revenues Fall Short
Revenue missed analyst estimates by 7.1%. Earnings per share (EPS) exceeded analyst estimates by 44%.
The company's shares are up 7.1% from a week ago.
Risk Analysis
We should say that we've discovered 3 warning signs for InDex Pharmaceuticals Holding (1 is a bit unpleasant!) that you should be aware of before investing here.
Valuation is complex, but we're helping make it simple.
Find out whether InDex Pharmaceuticals Holding is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
View the Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About OM:INDEX
InDex Pharmaceuticals Holding
InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis.
Flawless balance sheet and slightly overvalued.